inbiome

inbiome is a private, pre-revenue diagnostics company developing a revolutionary bacterial identification platform called Molecular Culture®. This technology combines proprietary chemistry and AI to detect all bacterial species in a sample within hours, overcoming the limitations of traditional culture and PCR methods. Initially optimized for joint aspirate analysis in infectious disease diagnostics, the platform has broad potential across infectious diseases and microbiome-based healthcare. The company collaborates with academic and clinical partners to validate and commercialize its technology, aiming to shift healthcare towards faster diagnostics and preventive strategies.

Molecular Culture®: A proprietary, non-selective bacterial profiling technique that detects all bacterial DNA, converts it to barcodes, and uses an AI platform to identify all species present within hours. It claims advantages over traditional culture and PCR in speed, sensitivity, and ability to detect uncultivable or antibiotic-treated bacteria.

inbiome competes in the rapid molecular diagnostics space against large established players (e.g., BioMérieux, Becton Dickinson, Roche) offering multiplex PCR panels and mass spectrometry, as well as other startups developing novel sequencing- or AI-based pathogen detection methods. Its differentiation lies in the claimed comprehensiveness (non-selective detection) and speed (hours) of its Molecular Culture® platform.